Wellness Intervention for Smoking and HIV

Description

The investigators propose to use a parallel group, randomized controlled trial to test the efficacy of a 13-week personalized approach to reducing smoking intervention versus a second approach using a different health intervention on smoking cessation, healthy sleep metrics, and biomarkers of cardiovascular risk in a sample of 200 treatment-seeking smokers who are adults living with HIV (ALHIV). To enroll in the study, treatment-seeking ALHIV smokers will undergo phone and in-person study eligibility assessments, including a history, physical examination, screening laboratory tests, and an overnight in-home objective sleep assessment. Eligible subjects (N=200) will be randomized to the 13-week Approach 1 (N=100) or Approach 2 (N=100) condition. All subjects will receive a 12-week course of varenicline (beginning in week 2) and 8 individual 15-minute smoking cessation counseling sessions \[weeks 1, 2, 3 (target quit date), 5, 7, 9, 11, 13\]. At each in-person counseling session, 30-45 minutes of Approach 1 or Approach 2 counseling will be provided as well. While receiving varenicline, the study team will monitor for side effects and changes to blood pressure at each study visit for safety reasons. Study measures are collected at all time points including EOT (week 13), and 6-month follow-up (6MFU).

Conditions

HIV, Sleep, Smoking Cessation, Cardiovascular Diseases

Talk to us

Study Overview

On this page

Study Details

Study overview

The investigators propose to use a parallel group, randomized controlled trial to test the efficacy of a 13-week personalized approach to reducing smoking intervention versus a second approach using a different health intervention on smoking cessation, healthy sleep metrics, and biomarkers of cardiovascular risk in a sample of 200 treatment-seeking smokers who are adults living with HIV (ALHIV). To enroll in the study, treatment-seeking ALHIV smokers will undergo phone and in-person study eligibility assessments, including a history, physical examination, screening laboratory tests, and an overnight in-home objective sleep assessment. Eligible subjects (N=200) will be randomized to the 13-week Approach 1 (N=100) or Approach 2 (N=100) condition. All subjects will receive a 12-week course of varenicline (beginning in week 2) and 8 individual 15-minute smoking cessation counseling sessions \[weeks 1, 2, 3 (target quit date), 5, 7, 9, 11, 13\]. At each in-person counseling session, 30-45 minutes of Approach 1 or Approach 2 counseling will be provided as well. While receiving varenicline, the study team will monitor for side effects and changes to blood pressure at each study visit for safety reasons. Study measures are collected at all time points including EOT (week 13), and 6-month follow-up (6MFU).

Using Sleep Health to Optimize Smoking Cessation Treatment Response in HIV-Positive Adults

Wellness Intervention for Smoking and HIV

Condition
HIV
Intervention / Treatment

-

Contacts and Locations

Phoenix

Banner University Medical Center Phoenix, Phoenix, Arizona, United States, 85006

Tucson

University of Arizona, Tucson, Arizona, United States, 85724

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Males and females 18 -75 years;
  • 2. Documented HIV infection;
  • 3. CD4+ T cell count ≥ 200 cells/mm3;
  • 4. On stable antiretroviral therapy without intention of changing, or not on antiretroviral therapy with no immediate intention to start;
  • 5. Smoke at least 5 cigarettes/day;
  • 6. Report wanting to quit smoking in the next month;
  • 7. Have no sleep disorders (with the exception of insomnia or mild to moderate obstructive sleep apnea (STOP-Bang score of 4 or less; apnea-hypopnea index (AHI) of less than 30);
  • 8. Able to communicate in English and provide written informed consent for study procedures;
  • 9. Able to use varenicline tartrate safely;
  • 10. Will be residing in the geographic area for at least 10 months;
  • 11. Willing to attend 8 in-person sessions and one 6-month follow up assessment.
  • 1. Regular use of chewing tobacco, snuff, cigars, e-cigarettes, unless willing to stop;
  • 2. Current enrollment or plans to enroll in another smoking cessation program or use other smoking cessation products for the duration of the study;
  • 3. Women of childbearing potential who are pregnant, lactating, or likely to become pregnant during the trial and unwilling to use contraception during the study;
  • 4. Unstable alcohol use that precludes reliable study participation as assessed by study physician;
  • 5. Unstable drug use that precludes reliable study participation as assessed by study physician;
  • 6. Unstable mental illness that precludes reliable study participation as assessed by study physician;
  • 7. A history of a suicide attempt within the last two years, and/or current nonspecific suicidal thoughts as defined by the Columbia Suicide Severity Rating Scale;
  • 8. Unstable or untreated moderate or severe depression as assessed by the Patient Health Questionnaire 9 (PHQ-9) scale. A participant with a score of ≥ 15 will be referred to one of the study's mental health clinicians (Dr. Michael Grandner or Dr. Susan Gorovoy) for further assessment of their depression
  • 9. Serious or unstable disease within the past 6 months (e.g., cancer, seizure disorder, end-stage liver disease, end-stage renal disease, uncontrolled diabetes, pulmonary disease requiring oxygen);
  • 10. Any prior history of seizure disorder within the past year;
  • 11. Unstable cardiac condition (i.e., angina, myocardial infarction, or coronary angioplasty) within the past 6 months or a clinically significant EKG that may present a health or safety risk as assessed by the study physician;
  • 12. Currently working night/rotating shift and/or use of a sleep medication, or a medication that could influence sleep;
  • 13. Prior history of adult somnambulism;
  • 14. Use of a sleep medication that will interfere with study results
  • 15. Inability to complete any of the study tasks as determined by the investigators.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Arizona,

Elizabeth Connick, MD, PRINCIPAL_INVESTIGATOR, University of Arizona

Michael Grandner, PhD, PRINCIPAL_INVESTIGATOR, University of Arizona

Study Record Dates

2025-05-31